摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-氨基-2-氯嘧啶 | 56621-90-0

中文名称
5-氨基-2-氯嘧啶
中文别名
2-氯-5-氨基嘧啶
英文名称
2-chloro-5-aminopyrimidine
英文别名
2-chloropyrimidin-5-amine;5-amino-2-chloropyrimidine;5-Amino-2-chlorpyrimidin
5-氨基-2-氯嘧啶化学式
CAS
56621-90-0
化学式
C4H4ClN3
mdl
MFCD06412560
分子量
129.549
InChiKey
DZBKIOJXVOECRA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    198-199℃
  • 沸点:
    338.8±15.0 °C(Predicted)
  • 密度:
    1.437±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    8
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    51.8
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    Xn
  • 安全说明:
    S22,S26,S36/37/39
  • 危险类别码:
    R22,R36,R36/37/38
  • 海关编码:
    2933599090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    室温

SDS

SDS:0b27987bd9432b8e3032ce1873bf46cb
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 5-Amino-2-chloropyrimidine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H319: Causes serious eye irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

Section 3. Composition/information on ingredients.
Ingredient name: 5-Amino-2-chloropyrimidine
CAS number: 56621-90-0

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C4H4ClN3
Molecular weight: 129.5

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

2-氯-5-氨基嘧啶是一种非常有用的嘧啶衍生物,也是一个重要的中间体化合物。

合成

将5-硝基脲嘧啶、三氯氧磷和有机碱按质量比1:5~10:3~7的比例混合后进行氯化反应,在30~105°C下反应2~6小时。反应完成后,冷却混合物并减压浓缩以去除多余的三氯氧磷。随后,加入水并用有机溶剂萃取,经过干燥和浓缩处理后得到中间产物2,4-二氯-5-硝基嘧啶。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5-氨基-2-氯嘧啶氢碘酸 作用下, 以 二氯甲烷 为溶剂, 反应 5.0h, 以85%的产率得到2-碘-5-氨基嘧啶
    参考文献:
    名称:
    新型大环三酰胺的合成及可调节的离子识别性能
    摘要:
    在这项工作中,我们报告了刚性大环三酰胺的合成及其作为选择性阴离子和金属受体的可调节离子识别特性。通过六甲基二硅叠氮化锂(LiHMDS)辅助环缩构反应制备了含二苯乙炔的环状三酰胺CTA-1b和三个带有官能甲氧基和嘧啶部分的环状三酰胺。CTA-1B显示强的结合亲和力,以氯-和我-阴离子,而CTA-2B显示了良好的结合亲和力的La 3+及Eu 3+的阳离子。通过将嘧啶和甲氧基结合到大环酰胺中,可以调节离子的选择性识别能力。
    DOI:
    10.1016/j.tet.2014.06.062
  • 作为产物:
    描述:
    2-羟基-5-硝基嘧啶三氯氧磷 作用下, 以 乙酸乙酯 为溶剂, 生成 5-氨基-2-氯嘧啶
    参考文献:
    名称:
    Pyrimidines as novel openers of potassium ion channels
    摘要:
    本发明提供了一类嘧啶酰胺,可用作钾离子通道的开启剂。该发明的化合物在治疗和诊断方法中均有用途。
    公开号:
    US20030181465A1
点击查看最新优质反应信息

文献信息

  • PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY
    申请人:Rewcastle Gordon William
    公开号:US20110009405A1
    公开(公告)日:2011-01-13
    Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazoles of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.
    本文提供了式I的嘧啶基和1,3,5-三嗪基苯并咪唑化合物,以及它们的药物组合物、制备方法,以及作为抗癌治疗药物或药剂的用途,可以单独使用,也可以与放疗和/或其他抗癌药物联合使用。
  • [EN] SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS<br/>[FR] ANALOGUES D'URÉE PONTÉS SUBSTITUÉS EN TANT QUE MODULATEURS DE SIRTUINE
    申请人:GLAXOSMITHKLINE IP NO 2 LTD
    公开号:WO2016079709A1
    公开(公告)日:2016-05-26
    The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
    本发明涉及一种新型的取代桥式脲类似物化合物,其化学式为(I)或其药学上可接受的盐,相应的药物组合物,制备这种化合物的方法以及单独使用或与其他治疗剂联合使用的这些化合物作为Sirtuin调节剂,可用于增加细胞寿命,并用于治疗和/或预防各种疾病和紊乱,包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块紊乱、炎症、癌症和/或潮红有关的疾病或紊乱,以及那些会受益于增加线粒体活性的疾病或紊乱。
  • FLAP MODULATORS
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:US20140221310A1
    公开(公告)日:2014-08-07
    The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R 1 , L and R 2 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.
    本发明涉及式(I)化合物,或其形式,其中环A,R1,L和R2如本文所定义,作为FLAP调节剂有用。该发明还涉及包含式(I)化合物的药物组合物。制备和使用式(I)化合物的方法也属于本发明的范围。
  • [EN] cGAS ANTAGONIST COMPOUNDS<br/>[FR] COMPOSÉS ANTAGONISTES DU CGAS
    申请人:IMMUNE SENSOR LLC
    公开号:WO2017176812A1
    公开(公告)日:2017-10-12
    Disclosed are novel compounds of Formula (I) that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.
    揭示了一种新型化合物的化学式(I),这些化合物是cGAS拮抗剂,涉及到这些化合物的制备方法、包含这些化合物的药物组合物,以及它们在医学治疗中的应用。
  • HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS
    申请人:Alvaro Giuseppe
    公开号:US20130267510A1
    公开(公告)日:2013-10-10
    The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.
    该发明提供了化合物的公式(I):所述化合物是Kv3通道的抑制剂,可用于预防或治疗相关疾病。
查看更多